The results of the SURPASS-CVOT will define the impact of tirzepatide on cardiovascular disease
C., Cheiran, G., Rocha, M
Results In the GLP-1 RA vs SGLT-2 inhibitor cohort (2014-2022) we identified 83,464 new users of GLP-1 RAs and 78,366 new users of SGLT-2 inhibitors
Firstly, the metabolic benefits of both treatments may be complementary
while immune progenitor-like cell clusters from adult killifish display markers of active proliferation and replication-independent DNA repair, immune cell progenitors from old killifish display increased markers of DNA damage
I'm not, you know, I'm 90%, 80% of the time I'm doing the right things the right way, I think, although I'm now going to improve on them with this new knowledge